Roland R Griffiths

List of Publications by Year
in descending order

105 papers	11,829 citations	38742 50 h-index	31849 101 g-index
110 all docs	110 docs citations	110 times ranked	4197 citing authors

#	Article	IF	Citations
1	Models of psychedelic drug action: modulation of cortical-subcortical circuits. Brain, 2022, 145, 441-456.	7.6	82
2	Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation. Frontiers in Neuroergonomics, 2022, 2, .	1.1	4
3	Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 2022, 36, 151-158.	4.0	162
4	A Single Belief-Changing Psychedelic Experience Is Associated With Increased Attribution of Consciousness to Living and Non-living Entities. Frontiers in Psychology, 2022, 13, 852248.	2.1	30
5	Phenomenology and content of the inhaled N, N-dimethyltryptamine (N, N-DMT) experience. Scientific Reports, 2022, 12, .	3.3	19
6	Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry, 2021, 78, 481.	11.0	648
7	Psychedelics in Psychiatryâ€"Keeping the Renaissance From Going Off the Rails. JAMA Psychiatry, 2021, 78, 469.	11.0	44
8	The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. ACS Pharmacology and Translational Science, 2021, 4, 568-572.	4.9	223
9	Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD. Journal of Psychopharmacology, 2021, 35, 437-446.	4.0	79
10	Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. Journal of Psychopharmacology, 2021, 35, 353-361.	4.0	49
11	Trends in the Top-Cited Articles on Classic Psychedelics. Journal of Psychoactive Drugs, 2021, 53, 283-298.	1.7	13
12	Errors in a Response Rate and in Effect Sizes in Study of Psilocybin-Assisted Therapy for Major Depressive Disorder. JAMA Psychiatry, 2021, 78, 569.	11.0	1
13	Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities. International Journal of Neuropsychopharmacology, 2021, 24, 615-623.	2.1	20
14	Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports. Pharmacopsychiatry, 2021, 54, 240-245.	3.3	29
15	Recent Progress in Lyme Disease and Remaining Challenges. Frontiers in Medicine, 2021, 8, 666554.	2.6	55
16	Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Translational Psychiatry, 2021, 11, 574.	4.8	115
17	The Potential of Psychedelics for End of Life and Palliative Care. Current Topics in Behavioral Neurosciences, 2021, , 169-184.	1.7	8
18	Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. Journal of Contextual Behavioral Science, 2020, 15, 39-45.	2.6	172

#	Article	IF	Citations
19	Prevalence and Correlates of Caffeine Use Disorder Symptoms Among a United States Sample. Journal of Caffeine and Adenosine Research, 2020, 10, 4-11.	0.6	10
20	The Acute Effects of the Atypical Dissociative Hallucinogen Salvinorin A on Functional Connectivity in the Human Brain. Scientific Reports, 2020, 10, 16392.	3.3	28
21	Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan. Psychopharmacology, 2020, 237, 2293-2304.	3.1	32
22	Emotions and brain function are altered up to one month after a single high dose of psilocybin. Scientific Reports, 2020, 10, 2214.	3.3	169
23	Inhaled 5-methoxy-N,N-dimethyltryptamine: Supportive context associated with positive acute and enduring effects. Journal of Psychedelic Studies, 2020, 4, 114-122.	1.2	14
24	Survey of entity encounter experiences occasioned by inhaled N,N-dimethyltryptamine: Phenomenology, interpretation, and enduring effects. Journal of Psychopharmacology, 2020, 34, 1008-1020.	4.0	64
25	Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic. Drug and Alcohol Dependence, 2020, 208, 107849.	3.2	98
26	Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. NeuroImage, 2020, 218, 116980.	4.2	92
27	Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology, 2019, 33, 1088-1101.	4.0	145
28	Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PLoS ONE, 2019, 14, e0214377.	2.5	132
29	5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. American Journal of Drug and Alcohol Abuse, 2019, 45, 161-169.	2.1	91
30	A randomized controlled trial of a manual-only treatment for reduction and cessation of problematic caffeine use. Drug and Alcohol Dependence, 2019, 195, 45-51.	3.2	7
31	Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. , 2019, 197, 83-102.		296
32	Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey. Frontiers in Psychiatry, 2019, 10, 955.	2.6	75
33	Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. Journal of Psychopharmacology, 2018, 32, 49-69.	4.0	285
34	Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. Psychopharmacology, 2018, 235, 521-534.	3.1	73
35	Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study. Frontiers in Psychology, 2018, 9, 2459.	2.1	54
36	Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. Journal of Psychopharmacology, 2018, 32, 756-769.	4.0	152

#	Article	IF	Citations
37	Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition. Psychopharmacology, 2018, 235, 2915-2927.	3.1	58
38	The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 2018, 142, 143-166.	4.1	184
39	The factor structure of the Mystical Experience Questionnaire (MEQ): Reply to Bouso et al., 2016. Human Psychopharmacology, 2017, 32, e2564.	1.5	9
40	Effects of caffeine on alcohol reinforcement: beverage choice, self-administration, and subjective ratings. Psychopharmacology, 2017, 234, 877-888.	3.1	14
41	An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. Journal of Psychopharmacology, 2017, 31, 841-850.	4.0	72
42	Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. Current Topics in Behavioral Neurosciences, 2017, 36, 393-430.	1.7	152
43	Potential Therapeutic Effects of Psilocybin. Neurotherapeutics, 2017, 14, 734-740.	4.4	180
44	Neuroticism is associated with challenging experiences with psilocybin mushrooms. Personality and Individual Differences, 2017, 117, 155-160.	2.9	54
45	Long-term follow-up of psilocybin-facilitated smoking cessation. American Journal of Drug and Alcohol Abuse, 2017, 43, 55-60.	2.1	430
46	Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 2016, 30, 1181-1197.	4.0	1,221
47	Weekly Energy Drink Use Is Positively Associated with Delay Discounting and Risk Behavior in a Nationwide Sample of Young Adults. Journal of Caffeine Research, 2016, 6, 10-19.	0.9	22
48	Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 2016, 30, 1268-1278.	4.0	303
49	The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. Journal of Psychopharmacology, 2016, 30, 1279-1295.	4.0	175
50	A brief manualized treatment for problematic caffeine use: A randomized control trial.. Journal of Consulting and Clinical Psychology, 2016, 84, 113-121.	2.0	11
51	Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans. Journal of Psychopharmacology, 2016, 30, 323-329.	4.0	12
52	Psilocybin, psychological distress, and suicidality. Journal of Psychopharmacology, 2015, 29, 1041-1043.	4.0	62
53	Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential. Psychopharmacology, 2015, 232, 871-883.	3.1	11
54	Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology, 2015, 29, 1182-1190.	4.0	318

#	Article	IF	Citations
55	Nicotine reinforcement in never-smokers. Psychopharmacology, 2015, 232, 4243-4252.	3.1	21
56	Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction. Current Drug Abuse Reviews, 2015, 7, 157-164.	3.4	306
57	Pilot study of the 5-HT_{2A}R agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 2014, 28, 983-992.	4.0	613
58	Caffeine Use Disorder: A Comprehensive Review and Research Agenda. Journal of Caffeine Research, 2013, 3, 114-130.	0.9	101
59	LC-MS/MS quantification of salvinorin A from biological fluids. Analytical Methods, 2013, 5, 7042.	2.7	5
60	A Critical Examination of the Caffeine Provisions in the Diagnostic and Statistical Manual, 5th Edition (DSM-5). Journal of Caffeine Research, 2013, 3, 101-107.	0.9	3
61	Caffeine Withdrawal and Dependence: A Convenience Survey Among Addiction Professionals. Journal of Caffeine Research, 2013, 3, 67-71.	0.9	22
62	Acute effects of zolpidem extended-release on cognitive performance and sleep in healthy males after repeated nightly use.. Experimental and Clinical Psychopharmacology, 2012, 20, 28-39.	1.8	48
63	High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology, 2012, 223, 1-15.	3.1	73
64	Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin. Journal for the Scientific Study of Religion, 2012, 51, 721-737.	1.5	243
65	Caffeine choice prospectively predicts positive subjective effects of caffeine and d-amphetamine. Drug and Alcohol Dependence, 2011, 118, 341-348.	3.2	11
66	Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology, 2011, 218, 649-665.	3.1	638
67	Evaluating Dependence Criteria for Caffeine. Journal of Caffeine Research, 2011, 1, 219-225.	0.9	31
68	Caffeine withdrawal, acute effects, tolerance, and absence of net beneficial effects of chronic administration: cerebral blood flow velocity, quantitative EEG, and subjective effects. Psychopharmacology, 2009, 204, 573-585.	3.1	70
69	Amnestic effects of sodium oxybate are less than those of triazolamâ€"reply to Drs. Zvosec and Smith. Psychopharmacology, 2009, 207, 511-512.	3.1	0
70	Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug and Alcohol Dependence, 2009, 105, S14-S25.	3.2	174
71	Ramelteon. CNS Drugs, 2005, 19, 1066-1067.	5.9	1
72	Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. Journal of Clinical Psychiatry, 2005, 66 Suppl 9, 31-41.	2.2	62

#	Article	IF	Citations
73	A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology, 2004, 176, 1-29.	3.1	438
74	The adenosine receptor antagonist CGS15943 reinstates cocaine-seeking behavior and maintains self-administration in baboons. Psychopharmacology, 2003, 168, 155-163.	3.1	48
75	Principles of initial experimental drug abuse liability assessment in humans. Drug and Alcohol Dependence, 2003, 70, S41-S54.	3.2	174
76	Acute dose-effects of scopolamine on false recognition. Psychopharmacology, 2001, 153, 425-433.	3.1	17
77	Reinforcing effects of oral cocaine: contextual determinants. Psychopharmacology, 2001, 154, 143-152.	3.1	18
78	Physiological, subjective and reinforcing effects of oral and intravenous cocaine in humans. Psychopharmacology, 2001, 156, 435-444.	3.1	43
79	Alcohol and false recognition: a dose-effect study. Psychopharmacology, 2001, 159, 51-57.	3.1	18
80	Effects of Triazolam on Brain Activity During Episodic Memory Encoding: A PET Study. Neuropsychopharmacology, 2001, 25, 744-756.	5.4	23
81	Acute effects of triazolam on false recognition. Memory and Cognition, 2000, 28, 1357-1365.	1.6	23
82	Triazolam and zolpidem: effects on human memory and attentional processes. Psychopharmacology, 1999, 144, 8-19.	3.1	64
83	Stable low-rate midazolam self-injection with concurrent physical dependence under conditions of long-term continuous availability in baboons. Psychopharmacology, 1998, 135, 70-81.	3.1	15
84	Benzodiazepine self-administration in humans and laboratory animals - implications for problems of long-term use and abuse. Psychopharmacology, 1997, 134, 1-37.	3.1	238
85	Alprazolam absorption kinetics affects abuse liability*. Clinical Pharmacology and Therapeutics, 1995, 57, 356-365.	4.7	60
86	DISCRIMINATIVE STIMULUS EFFECTS OF DIAZEPAM AND BUSPIRONE IN NORMAL VOLUNTEERS. Journal of the Experimental Analysis of Behavior, 1995, 63, 277-294.	1.1	26
87	A PROCEDURE FOR STUDYING THE WITHIN-SESSION ONSET OF HUMAN DRUG DISCRIMINATION. Journal of the Experimental Analysis of Behavior, 1994, 61, 181-189.	1.1	6
88	LOW-DOSE CAFFEINE DISCRIMINATION AND SELF-REPORTED MOOD EFFECTS IN NORMAL VOLUNTEERS. Journal of the Experimental Analysis of Behavior, 1992, 57, 91-107.	1.1	65
89	Abuse liability assessment of anxiolytics/ hypnotics: rationale and laboratory lore. Addiction, 1991, 86, 1625-1632.	3.3	29
90	Self-injection of barbiturates, benzodiazepines and other sedative-anxiolytics in baboons. Psychopharmacology, 1991, 103, 154-161.	3.1	96

#	Article	IF	Citations
91	Asymmetrical cross-generalization in drug discrimination with lorazepam and pentobarbital training conditions. Drug Development Research, 1989, 16, 355-364.	2.9	47
92	Diazepam and triazolam self-administration in sedative abusers: concordance of subject ratings, performance and drug self-administration. Psychopharmacology, 1989, 99, 309-315.	3.1	34
93	REINFORCING EFFECTS OF CAFFEINE IN COFFEE AND CAPSULES. Journal of the Experimental Analysis of Behavior, 1989, 52, 127-140.	1.1	67
94	HUMAN COFFEE DRINKING: MANIPULATION OF CONCENTRATION AND CAFFEINE DOSE. Journal of the Experimental Analysis of Behavior, 1986, 45, 133-148.	1.1	46
95	Naloxone does not affect cigarette smoking. Psychopharmacology, 1986, 89, 261-4.	3.1	78
96	Effects of mecamylamine on human cigarette smoking and subjective ratings. Psychopharmacology, 1986, 88, 420-5.	3.1	128
97	Diazepam and methadone interactions in methadone maintenance. Clinical Pharmacology and Therapeutics, 1984, 36, 534-541.	4.7	70
98	Cigarette smoking and subjective response in alcoholics: Effects of pentobarbital. Clinical Pharmacology and Therapeutics, 1983, 33, 806-812.	4.7	46
99	Human progressive-ratio performance: Maintenance by pentobarbital. Psychopharmacology, 1983, 79, 4-9.	3.1	30
100	Effects of caffeine on cigarette smoking and subjective response. Clinical Pharmacology and Therapeutics, 1983, 34, 612-622.	4.7	81
101	Smoking behavior and tobacco smoke intake: Response of smokers to shortened cigarettes. Clinical Pharmacology and Therapeutics, 1982, 32, 90-97.	4.7	27
102	An automated version of the digit symbol substitution test (DSST). Behavior Research Methods, 1982, 14, 463-466.	4.0	325
103	CHOICE BETWEEN FOOD AND HEROIN: EFFECTS OF MORPHINE, NALOXONE, AND SECOBARBITAL. Journal of the Experimental Analysis of Behavior, 1981, 35, 335-351.	1.1	39
104	Opioids: Similarity between evaluations of subjective effects and animal selfâ€administration results. Clinical Pharmacology and Therapeutics, 1979, 25, 611-617.	4.7	118
105	Substance Abuse: Caffeine Use Disorders. , 0, , 1019-1040.		7